Health Canada Approves Levemir FlexTouch Prefilled Insulin Pen for the Treatment of Type 1 and Type 2 Diabetes
Novo Nordisk has announced that Health Canada has approved Levemir FlexTouch, a disposable prefilled insulin pen containing Levemir (insulin detemir). Levemir FlexTouch has been designed to improve ease of use for insulin administration and to help decrease barriers to good treatment adherence for Canadians living with type 1 and type 2 diabetes mellitus (diabetes).
The approval was also announced at the 2013 Vascular Conference in Montreal, Quebec.
Levemir FlexTouch features a push-button that does not extend at any set dose and a unique spring-loaded mechanism, in which the injection is driven by a torque spring rather than the user's thumb pressure.(1) The torque spring is loaded as the dose is set and the spring energy is activated by depressing the push-button. As a result, the injection force of FlexTouch is significantly lower than other widely used prefilled pens.(2) In 2012, Novo Nordisk announced the Health Canada approval of NovoRapid FlexTouch, which provided Canadians living with diabetes with the first prefilled insulin pen without a push-button extension for NovoRapid (insulin aspart).(3)
"Insulin treatment regimens can present challenges for many Canadians living with type 1 or type 2 diabetes, such as the convenience of insulin delivery, the anxiety associated with injections or the confidence in injection accuracy,"(4) said Dr Robert Schlosser, MD, FRCPC, Co-director of the LMC Endocrinology Centre, Thornhill, Ontario. "The approval of Levemir FlexTouch can help to address these barriers for those prescribed a long-acting basal insulin, resulting in improved treatment adherence."
Research indicates that insulin pens with relatively low injection force have been rated as easier and more comfortable to use by people with diabetes.(5) In clinical studies, FlexTouch was found to have design features and a functionality that make it an attractive device for insulin delivery.(6)
It is anticipated that Levemir FlexTouch will be available in Canada in January 2014.
References
[1] Oyer et al., Expert Opinion on Drug Delivery, 2011, 8(10):1259-1269, Pg 1260.
[2] Oyer et al., Expert Opinion on Drug Delivery, 2011, 8(10):1259-1269, Pg 1260.
[3] NovoRapid((R)) Product Monograph, 8 December 2011.
[4] Schipper et al., Current Medical Research & Opinion, 2012, 28(8):1297-1303
[5] Oyer et al., Expert Opinion on Drug Delivery, 2011, 8(10):1259-1269, Pg 1260.
[6] Schipper et al., Current Medical Research & Opinion, 2012, 8(8):1297-1303.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance